Abstract There is worldwide demand for therapies to promote the robust repair and regeneration with maximum regain of function of particular tissues and organs damaged by disease or injury. The potential role of adult stem cells has been highlighted by an increasing number of in vitro and in vivo studies. Nowhere is this more evident than in adult stem cell-based therapies being explored to promote cardiac regeneration. In spite of encouraging advances, significant challenges remain.
With an ever-increasing interest in actualizing the regenerative potential of adult stem cells, studies exploring the utility of adult stem cells in tissue and organ regeneration have also intensified [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Observations from both in vitro and in vivo studies have been encouraging to the point that it is expected that stem cells will become a critical player in regenerative medicine for many diseases and conditions. While there is reason for optimism, sometimes daunting challenges remain vis-à-vis identification of the most effective cell sources, improvement of transplant delivery methods and achieving sustained or functional integration of transplanted cells at injured sites before any of these observations can be efficiently translated to the clinical setting [11] . Nowhere is the optimism and challenge more acute than in the realm of cardiac repair.
Cardiovascular diseases damage the heart, resulting in loss of cardiac function, and contributing to the high cardiovascular-related incidence of morbidity and mortality worldwide [12, 13] The soaring incidence of cardiovascular disease, coupled with the limited availability and challenges of organ transplants, has driven many to look to stem cell therapy as a practical and attractive alternative. The optimism had been fueled by the exciting and compelling increase in our understanding of cardiac cells, their lineage and maturation sequence, and regulation of their function [14] [15] [16] [17] . However, with the increased knowledge has come increased understanding of the scope of the challenges. For example, how epigenetic changes regulate and modify not just normal development but contribute to disease states and capacity of stem cells to contribute to organ regeneration is only beginning to be explored [18] . More broadly, understanding of how to achieve sustained repair of damaged cardiac tissue via stimulation of endogenous stem cells or use of transplanted stem cells is still relatively limited [12, [19] [20] [21] . Nevertheless, as the papers within a recent special issue of Stem Cell Reviews and Reports (2013 #3) document, there remains reason for optimism and continued study.
Amongst areas of intense interest are those related to exploring and identifying potential cell populations suitable for repair of injured cardiac tissue, be it repair by donor cells themselves or induction of endogenous cells or combinations of the two. Some approaches are focusing on developing and improving isolation, ex vivo expansion, and manipulation of appropriate cells for excellent engraftment and capacity to promote endogenous cardiac repair [22] [23] [24] [25] [26] [27] . The identification of subpopulations of stem cells within cardiac tissue itself has provided new perspectives around patient-specific protocols for cardiac diseases [28] [29] [30] [31] [32] . This approach is aligned with the more general approach being studied of how to tap into the crucial cell types that participated in cardiac development originally. Other cell types being explored for cell-based therapy include bone marrowderived mononuclear cells, bone marrow-derived mesenchymal stem cells, cardiac-derived c-kit + stem cells and cardio sphere-derived cells. For any of these cell types to become valuable in a clinical setting, it is imperative that they are well characterized. Thus, significant efforts are going towards characterization of the multiple cell populations of interest, including characterization of their stemness and self-renewal capacity, their differentiation potential into functional cell types, and their responsiveness to various regulators and activators.
Activation and/or differentiation of putative stem and precursor cell populations via various signaling factors is an area of intense interest. Recent studies with epicardialresident stem cells, which are known to differentiate into cardiomyocytes during cardiac development in response to certain factors available at appropriate developmental times, underscore the excitement. For example, thymosin beta 4, a peptide critical for cardiac development and with cardioprotective properties, was recently shown to induce differentiation of epicardium-derived progenitor cells (EPDCs) into cardiomyocytes in the adult heart of a small animal model of myocardial infarction, but the data also suggest that there is a distinct window of opportunity for it to be effective [33] .
Amongst the various stem and progenitor cell types being investigated, mesenchymal stem cells (MSCs) are one of the most popular [34] . MSCs or MSC-like cells have been derived from a variety of sources including bone marrow and umbilical cord blood. They have been widely tested in preclinical studies and several clinical trials have evaluated their efficacy in cardiac repair. However, the specific role(s) of MSCs in cardiac repair remains unclear and, as noted above, it is likely that it is MSC-cardiac cell interactions that are important. While there remains intense interest and ongoing studies, to date the clinical application of MSCs for mainstream cardiovascular use has been hindered by several important limitations, including suboptimal retention, engraftment and survival and restricted capacity for bona fide cardiomyocyte regeneration. The question of which stem cells are best for a given type of injury or any cardiac injury is an important and challenging one [35] . Head-to-head comparisons of different cell types are still relatively rare. However, in one such study, cardiac stem cells were found to be superior to MSCs in modulating the electrophysiological abnormality and improving the ventricular fibrillation threshold in rats with myocardial infarction [36] .
Cardiac disease and the need for cardiac repair is often accompanied by co-morbidities that may influence the outcomes. For example, diabetes is recognized as an important risk factor for peripheral arterial disease, but little is not known about how type II diabetes affects the therapeutic function of adult stem cells, including MSCs. The impact of type II diabetes on the therapeutic efficacy of MSCs in revascularization after the induction of hindlimb ischemia has been investigated using experimental type II diabetes in db/db mice. It was observed that diabetes impaired MSCs' therapeutic function by favoring their differentiation towards adipocytes, while limiting their differentiation towards endothelial cells as a consequence of oxidative stress [37] . Although it is not known yet whether the human systems act the same way, it does point towards a therapeutic approach in which reversing the oxidative stress prior to MSC transplantation may be useful [37] .
Tissue engineering with specialized scaffolds, with or without stem or progenitor cells, is another approach to providing personalized solutions to the problem of cardiac muscle repair. Inclusion of stem cells with newer classes of composite materials has emerged to take advantage of the benefits of the strengths and minimize the weaknesses of both synthetic and natural materials [38] [39] [40] [41] . New developments to fabricate synthetic and hybrid scaffolds to be employed as cell delivery systems and the acknowledgement that surface physical, mechanical, chemical properties can exert specific effects on stem cells appear to be very exciting areas for further studies. In this respect, a cardiac-specific scaffold favoring stem cell electromechanical coupling with host tissue, while also promoting the vascularization of the newly formed tissue, is of interest [42] . Such biomimetic approaches, combined with ability to comply with cardiac muscle architecture, and deformability to sustain cardiac contraction are relevant and worth further investigation.
While preclinical research has advanced into early phase clinical trials in patients, few late-phase clinical trials have been conducted. Sources of donor stem cells, autologous versus allogeneic cell sources, types or lineages of cells, remain critically important considerations [43] . It has been noted that public perception of stem cell therapy as well as manufacturing challenges and the regulatory environment all contribute to the small number of late phase (Phase 3) clinical trials undertaken to date and the lack of Food and Drug Administration (FDA) approvals in the US [43] . Nevertheless, there is progress being made and some data with mixed cell populations are interesting. For example, Aastrom Biosciences has developed a proprietary cellprocessing technology, ixmyelocel-T, a patient-specific multicellular therapy based on expansion of cells from a small sample of a patient's own bone marrow [43, 44] . Ixmyelocel-T uses current good manufacturing practices to expand the MSCs and macrophages. The rationale is that the mixture of expanded MSCs and activated macrophages promotes longterm tissue repair of ischemic tissue. Clinical trial data collected to date support the potential for ixmyelocel-T as an efficacious and safe treatment for ischemic cardiovascular indications, including critical limb ischemia and a severe form of heart failure, dilated cardiomyopathy (DCM). The CLI clinical program has completed phase 2 and agreement has been reached for an FDA-approved phase 3 study (REVIVE) through the Special Protocol Assessment process [43] [44] [45] [46] .
In summary, great interest in stem cell therapies remains but so too do challenges. It is notable that while data are accumulating from basic and translational work that point to the beneficial effects of stem cell therapy, the mechanisms involved in stem cell therapy remain unclear and much preclinical work has not been translated into humans. Hopefully, the studies presented in a recent volume will spur additional work towards addressing the challenges.
